Inactivation of p16INK4a expression in malignant mesothelioma by methylation

Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998;113:66S–73S. Antman, 1989, Benign and malignant mesothelioma, 1399 Cheng, 1994, p16 alterations and deletion mapping of 9p21–p22 in malignant mesothelioma, Cancer Res., 54, 5547 Sherr, 1996, Cancer cell cycles, Science, 274, 1672, 10.1126/science.274.5293.1672 Quelle, 1995, Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest, Cell, 83, 993, 10.1016/0092-8674(95)90214-7 Yang, 2000, Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells, J. Natl. Cancer Inst., 92, 636, 10.1093/jnci/92.8.636 Frizelle, 2000, Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus, Cancer Gene Ther., 7, 1421, 10.1038/sj.cgt.7700241 Frizelle, 1998, Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression, Oncogene, 16, 3087, 10.1038/sj.onc.1201870 Kratzke, 1995, Immunohistochemical analysis of the p16INK4 cyclin-dependent kinase inhibitor in malignant mesothelioma, J. Natl. Cancer Inst., 87, 1870, 10.1093/jnci/87.24.1870 Kamb, 1994, Analysis of the p16 gene (CDKN2) as a candidate for the chromsome 9p melanoma susceptibility locus, Nat. Genet., 8, 22, 10.1038/ng0994-22 Kamb, 1994, A cell cycle regulator potentially involved in genesis of many tumor types, Science, 264, 436, 10.1126/science.8153634 Belinsky, 1998, Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis, Proc. Natl. Acad. Sci. USA, 95, 11891, 10.1073/pnas.95.20.11891 Otterson, 1995, CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by 5-aza 2′deoxycytidine, Oncogene, 11, 1211 Zhou, 2001, Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer, Lung Cancer, 32, 27, 10.1016/S0169-5002(00)00210-5 Herman, 1995, Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers, Cancer Res., 55, 4525 Hou, 1999, DNA methylation and expression of p16(INK4A) gene in pulmonary adenocarcinoma and anthracosis in background lung, Int. J. Cancer, 84, 609, 10.1002/(SICI)1097-0215(19991222)84:6<609::AID-IJC12>3.0.CO;2-Q Kashiwabara, 1998, Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers, Int. J. Cancer, 79, 215, 10.1002/(SICI)1097-0215(19980619)79:3<215::AID-IJC1>3.0.CO;2-S Swafford, 1997, Frequent aberrant methylation of p16INK4a in primary rat lung tumors, Mol. Cell. Biol., 17, 1366, 10.1128/MCB.17.3.1366 Shapiro, 1995, Multiple mechanisms of p16INK4A inactivation in non-small cell lung cancer cell lines, Cancer Res., 55, 6200 Zhou, 2001, Mechanisms of G1 checkpoint loss in resected early stage non-small cell lung cancer, Lung Cancer, 32, 27, 10.1016/S0169-5002(00)00210-5 Vonlanthen, 1998, Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression, Oncogene, 17, 2779, 10.1038/sj.onc.1202501 Cheson, 2000, Novel therapeutic agents for the treatment of myelodysplastic syndromes, Semin. Oncol., 27, 560 Quesnel, 1999, P15INK4b gene methylation and myelodysplastic syndromes, Leuk. Lymphoma, 35, 437, 10.1080/10428199909169608 Silverman, 1993, Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes, Leukemia, 7, 21 Uchida, 1997, Hypermethylation of the p15INK4B gene in myelodysplastic syndromes, Blood, 90, 1403, 10.1182/blood.V90.4.1403 Quesnel, 1998, Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression, Blood, 91, 2985, 10.1182/blood.V91.8.2985.2985_2985_2990 Daskalakis M, Nguyen TT, Wijermans P, Jones PA, Lubbert M. Frequent hypermethylation of p15/INK4b in patients with myelodysplastic syndromes is decreased following treatment with 5-aza-2′-deoxycytidine (Decitabine). In: American Society of Hematology 40th annual meeting, Miami Beach, FL, 1998. Vogelzang, 1997, Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B, Cancer, 79, 2237, 10.1002/(SICI)1097-0142(19970601)79:11<2237::AID-CNCR23>3.0.CO;2-W Samuels, 1998, Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B, Cancer, 82, 1578, 10.1002/(SICI)1097-0142(19980415)82:8<1578::AID-CNCR21>3.3.CO;2-U Pass, 1995, Characteristics of nine newly derived mesothelioma cell lines, Ann. Thorac. Surg., 59, 835, 10.1016/0003-4975(95)00045-M Pass, 1996, In vitro and in vivo studies of mesothelioma, J. Cell. Biochem. Suppl., 24, 142, 10.1002/jcb.240630509 Herman, 1996, Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands, Proc. Natl. Acad. Sci. USA, 93, 9821, 10.1073/pnas.93.18.9821 Toyooka, 2001, Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma, Cancer Res., 61, 5727 De Luca, 1997, The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas, Nat. Med., 3, 913, 10.1038/nm0897-913 Otterson, 1994, Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB, Oncogene, 9, 3375